PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 2026European Respiratory Journal0 citations

Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin

View Full Paper
CWChristiane WhetstoneMcMaster UniversityNDNermin DiabMcGill University Health CentreDBDanica BristerUniversity of Calgary

Key Points

  • To discuss the role of eosinophils in refractory chronic cough and the impact of mepolizumab.
  • Evaluation of the MUCOSA trial findings on mepolizumab's effects on cough frequency.
  • Analysis of eosinophil markers in blood and sputum.
  • Mepolizumab reduced levels of blood and sputum eosinophils.
  • Eosinophil-derived neurotoxin levels remained unchanged.

Abstract

Extract Reply to W. Zhan and co-workers: The recently published MUCOSA trial in the European Respiratory Journal, which evaluated the effects of mepolizumab on objective cough frequency in patients with refractory chronic cough (RCC), has prompted a re-evaluation of the role of eosinophils in cough pathophysiology 1.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Whetstone et al. (2026) studied this question.

synapsesocial.com/papers/69fecfe9b9154b0b82876d6ehttps://doi.org/10.1183/13993003.00143-2026
Ask AI
Helpful
Bookmark
Share
View Full Paper